Home›Stocks›OTLK

OTLK — structural market context

Outlook Therapeutics, Inc. Com

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

OTLK short interest & days to cover

SHARES SHORT

20.0M

% OF FLOAT

—

DAYS TO COVER

1.1

CHANGE VS PRIOR

+78.0%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-07-31 (15d ago)

OTLK fails-to-deliver (FTD)

Settlement date	Failed shares	Price
2026-07-14 · 32d	121K	$1.55
2026-07-09 · 37d	68K	$1.69
2026-07-08 · 38d	1K	$1.46

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

OTLK insider buying and selling (Form 4)

Last 12 months, open-market only: 6 purchases · 0 sales · 3 distinct buyers in 30 days

Insider	Type	Shares	Value	Filed
Jahr Robert Charles · director, officer: Chief Executive Officer	Buy (P)	152K	$150K	2026-08-14
Jahr Robert Charles · director, officer: Chief Executive Officer	Buy (P)	152K	$167K	2026-08-14
Sukhtian Ghiath M. · director, 10 percent owner:	Buy (P)	2.5M	$2.5M	2026-08-14
Sukhtian Ghiath M. · director, 10 percent owner:	Buy (P)	2.5M	$2.8M	2026-08-14
KENYON LAWRENCE A · director, officer: Chief Financial Officer	Buy (P)	101K	$100K	2026-08-14

SEC Form 4 filings, open-market purchases and sales only (codes P and S); grants and option exercises excluded. Attributed public records.

Frequently asked questions

Are insiders buying OTLK?

In the last 12 months of SEC Form 4 filings, OTLK recorded 6 open-market insider purchases and 0 open-market sales (codes P and S; grants and option exercises excluded). 3 distinct insiders bought within the last 30 days. These are attributed public records — information, not instruction.

Is this page telling me to buy or sell OTLK?

No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.

All covered stocks Short Interest & FTD tracker Insider Buying tracker Analyst Accuracy tracker The platform

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.